Net sales by geographic region
Change on 2007 Change on
2007 Q3 a 9-month a
net comparable net comparable
euro million sales basis sales basis
Europe 2,978 +1.0% 9,128 -0.3%
United States 2,449 +6.1% 7,293 +8.1%
Other countries 1,598 +8.5% 4,720 +9.3%
TOTAL 7,025 +4.4% 21,141 +4.5%
Europe reported slight growth in the third quarter, but continues to be affected by a decline in net sales in France and Germany. In the nine months to end September, net sales fell by 0.3%, with the introduction of generics of Eloxatin(R) paring approximately 1.6% off sales growth for the period.
In the United States, third-quarter net sales rose by 6.1% despite the full effect of generic versions of Ambien(R) IR, which went off patent on April 20, 2006. Excluding the impact of Ambien(R) IR generics, net sales growth in the United States was 23.4%, thanks largely to a very fine performance from the Human Vaccines business.
In the nine months to end September, net sales rose by 8.1%, or by 18.2% excluding the impact of Ambien(R) IR generics from April.
In the "Other countries" region, third-quarter net sales were up 8.5%, driven by Latin America, Japan, the Middle East and Africa. Japan performed particularly well in the third quarter, posting double-digit growth thanks to an acceleration in sales growth for Plavix(R). In the nine months to end September, net sales in the "Other Countries" region rose by 9.3%.
Adjusted consolidated income statement
The adjusted consolidated income statement is presented in Appendix 3.
Refer to Appendix 1 for a definition
Copyright©2007 PR Newswire.
All rights reserved